CTNM (Contineum Therapeutics) ROE % Adjusted to Book Value : -14.94% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics ROE % Adjusted to Book Value?

Contineum Therapeutics's ROE % for the quarter that ended in Dec. 2024 was -28.54%. Contineum Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was 1.91. Contineum Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -14.94%.

Contineum Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Contineum Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics ROE % Adjusted to Book Value Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Negative Equity

-34.01

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial						-	-	-24.42	-8.21	-14.94

Competitive Comparison of Contineum Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Contineum Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Contineum Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Contineum Therapeutics ROE % Adjusted to Book Value Calculation

Contineum Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-64.95%	/	1.91
	=	-34.01%

Contineum Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-28.54%	/	1.91
	=	-14.94%

Contineum Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

3565 General Atomics Court, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.